Correlation Between Inhibrx and Sothebys
Specify exactly 2 symbols:
By analyzing existing cross correlation between Inhibrx and Sothebys 7375 percent, you can compare the effects of market volatilities on Inhibrx and Sothebys and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inhibrx with a short position of Sothebys. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inhibrx and Sothebys.
Diversification Opportunities for Inhibrx and Sothebys
Very weak diversification
The 3 months correlation between Inhibrx and Sothebys is 0.4. Overlapping area represents the amount of risk that can be diversified away by holding Inhibrx and Sothebys 7375 percent in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Sothebys 7375 percent and Inhibrx is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inhibrx are associated (or correlated) with Sothebys. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Sothebys 7375 percent has no effect on the direction of Inhibrx i.e., Inhibrx and Sothebys go up and down completely randomly.
Pair Corralation between Inhibrx and Sothebys
Given the investment horizon of 90 days Inhibrx is expected to generate 1.04 times more return on investment than Sothebys. However, Inhibrx is 1.04 times more volatile than Sothebys 7375 percent. It trades about -0.03 of its potential returns per unit of risk. Sothebys 7375 percent is currently generating about -0.25 per unit of risk. If you would invest 1,580 in Inhibrx on September 2, 2024 and sell it today you would lose (54.00) from holding Inhibrx or give up 3.42% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Weak |
| Accuracy | 76.19% |
| Values | Daily Returns |
Inhibrx vs. Sothebys 7375 percent
Performance |
| Timeline |
| Inhibrx |
| Sothebys 7375 percent |
Inhibrx and Sothebys Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Inhibrx and Sothebys
The main advantage of trading using opposite Inhibrx and Sothebys positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inhibrx position performs unexpectedly, Sothebys can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sothebys will offset losses from the drop in Sothebys' long position.| Inhibrx vs. Crinetics Pharmaceuticals | Inhibrx vs. Merus BV | Inhibrx vs. Lyell Immunopharma | Inhibrx vs. Kronos Bio |
| Sothebys vs. BioNTech SE | Sothebys vs. Inhibrx | Sothebys vs. Tscan Therapeutics | Sothebys vs. Asure Software |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Complementary Tools
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |